Neuropathy in cancer patients or patients with peripheral neuropathy is a common and often difficult and
debilitating complication of cancer or the treatment-related. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
is most widely reported and has been the focus of research efforts among the various types of neuropathies in
cancer patients. Platinum-based drugs, such as cisplatin and oxaliplatin, are well-known for inducing chronic
sensory neuropathies, but their acute and motor neurotoxicities are less well characterized.
Multidisciplinary team was charged with the review the literature and discussion intervention strategies currently
available to patients as well as areas that require research efforts for the possible prevention, diagnosis, and
management of peripheral neuropathy.
Effective management of neuropathy or CIPN depends on early diagnosis and an understanding of its underlying
causes in the individual patient. Patients with neuropathic pain (NP) are also challenging to manage and evidencebased
clinical recommendations for pharmacologic management are needed.
The objectives of this article are to discuss: Systematic literature reviews, randomized clinical trials, and existing
guidelines were evaluated in prevention, assessment and treatment of the various types of neuropathies in cancer
patients
PDF Links
Full text via DOI
Download Citation 
